Patent licensed from Johns Hopkins University for PCR-based companion diagnostics for cancer treatments

02-10-2010

QIAGEN announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. Research has shown that variation in the PI3K gene could be a key biomarker for use as a ...

more

09-24-2009

QIAGEN N.V. announced that it has acquired DxS Ltd (DxS), a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, United Kingdom. The transaction is valued at approximately US$ 95 million in cash (subject to customary purchase price ...

more

01-29-2009

DxS Ltd has announced the appointment of Jeff Devlin as Chief Operating Officer. Prior to DxS, Jeff held positions as Executive VP and Executive Committee member of Shire Pharmaceuticals, where he played a key role in strategy and integration. Before this he was a Partner in Ernst and ...

more

Company also announces Award of ISO 13485 certification

05-27-2008

DxS has announced plans to expand its manufacturing facilities, and to significantly increase the number of staff. In addition, the Company has also been awarded the ISO 13485:2003 quality certification for the "design, development and manufacture of molecular diagnostic products for human ...

more

01-15-2008

Epigenomics AG (and DxS Ltd. announced that they have entered into a strategic cross-licensing agreement. Under the terms of the agreement, Epigenomics obtains worldwide non-exclusive rights to DxS' proprietary Scorpions® technology for R&D use and research kits, as well as an option to ...

more

11-30-2006

DxS has won a 'Biotechnology Project of the Year' award for its highly sensitive EGFR (Epidermal Growth Factor Receptor) Mutation Test Kit. Sponsored by the Manchester based law firm Pannone LLP, the award was presented by Bionow, the Northwest Regional Development Agency's (NWDA) ...

more